DEL-1 and Thromboxane A2 in Diabetic Nephropathy Patients
For patients and families
In plain language
An automatic summary of structured registry data. It is an orientation aid, not a substitute for the official protocol or a physician assessment.
- What is being studied
- The protocol lists: No intervention.
- Who it may be relevant to
- Registry conditions: Nephropathy, Diabetic. Basic parameters: 18 years — 70 years · All.
- What needs checking
- Age, condition and sex are only basic indicators. Prior treatment, laboratory values and other mandatory requirements appear in the eligibility criteria below.
- Where it takes place
- Center list to be confirmed — check the primary protocol.
- Next step
- Save the trial, show it to the treating physician, and confirm current recruitment with the study center. Costs, documents and travel →
Unsure about the terms? Read our patient guide →
Official title
Developmental Endothelial Locus-1 Serum Level and Its Relation With Thromboxane A2 and Platelet Count in Patients With Diabetic Nephropathy
Overview
Diabetic nephropathy is one of the most common microvascular complications of diabetes mellitus and a leading cause of chronic kidney disease. Inflammation and platelet activation are believed to play a significant role in its pathogenesis and progression. Developmental endothelial locus-1 (DEL-1) is an anti-inflammatory protein that regulates leukocyte adhesion and endothelial function, while thromboxane A2 is a marker of platelet activation and contributes to vascular dysfunction. This study aims to evaluate serum levels of DEL-1 and thromboxane A2, and their relationship with platelet count in patients with diabetic nephropathy. Additionally, the study investigates the correlation between these biomarkers and disease severity. This observational cross-sectional study will be conducted on 80 participants, including patients with diabetic nephropathy and healthy controls, to explore the potential role of these biomarkers in disease progression and their possible use as diagnostic or prognostic indicators.
Interventions
- Other No intervention
No intervention is applied. This is an observational study involving clinical assessment and blood sample collection for laboratory analysis only.
Primary outcome measures
- Serum level of Developmental Endothelial Locus-1 (DEL-1). Time Frame: Baseline [Time frame: Baseline]
Eligibility criteria
Inclusion criteria
- Adult patients aged between 18 and 70 years.
- Patients diagnosed with diabetic nephropathy based on clinical and laboratory findings.
- Patients undergoing evaluation or follow-up for diabetic kidney disease.
- Ability and willingness to provide informed consent.
Exclusion criteria
- \- Patients with known hepatic disease.
- Patients with significant cardiovascular disease.
- Patients with malignancy.
- Patients who have undergone recent surgery.
- Patients with known hematological disorders or hypercoagulable states.
- Patients receiving medications that significantly affect platelet function.
Criteria are shown verbatim from the registry (in English). Final eligibility is always assessed by the study center.
Study design
- Observational model
- Case-control
Study locations
Center list to be confirmed — check the primary protocol.
Identifiers
NCT: NCT07749664 · DEL1-DN-2025 · ASWU-MD-2025-DEL1